News Headlines Article

Tricor doesn’t lower diabetics’ heart risk in large study
USA Today

A drug taken for decades by millions of people with type 2 diabetes to prevent heart attacks, strokes and deaths offered no benefit in a broad group of patients, a study released Sunday shows. Fenofibrate, sold as Tricor, lowers triglycerides and boosts good cholesterol, seemingly lowering heart risk. But in most type 2 diabetes patients, it failed to achieve the goal of reducing a combination of heart attacks, strokes and deaths, says lead investigator Henry Ginsberg of Columbia University.